John A Lambert Net Worth

The estimated Net Worth of John A Lambert is at least $1.08 Millón dollars as of 2 July 2009. John Lambert owns over 34,746 units of Novavax stock worth over $983,200 and over the last 18 years John sold NVAX stock worth over $97,984.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

John Lambert NVAX stock SEC Form 4 insiders trading

John has made over 1 trades of the Novavax stock since 2009, according to the Form 4 filled with the SEC. Most recently John sold 34,746 units of NVAX stock worth $97,984 on 2 July 2009.

The largest trade John's ever made was selling 34,746 units of Novavax stock on 2 July 2009 worth over $97,984. On average, John trades about 4,964 units every 0 days since 2007. As of 2 July 2009 John still owns at least 80,000 units of Novavax stock.

You can see the complete history of John Lambert stock trades at the bottom of the page.

What's John Lambert's mailing address?

John's mailing address filed with the SEC is C/O NOVAVAX, INC., 9920 BELWARD CAMPUS DRIVE, ROCKVILLE, MD, 20850.

Insiders trading at Novavax

Over the last 23 years, insiders at Novavax have traded over $136,088,511 worth of Novavax stock and bought 2,908,869 units worth $5,634,467 . The most active insiders traders include David M Mott, Rajiv I. Modi y Gary C Evans. On average, Novavax executives and independent directors trade stock every 25 days with the average trade being worth of $907,678. The most recent stock trade was executed by John Trizzino on 19 August 2024, trading 655 units of NVAX stock currently worth $8,050.

What does Novavax do?

novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"​), seasonal influenza, pandemic influenza, and ebola virus ("ebov"​). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.

Complete history of John Lambert stock trades at Novavax

Novavax executives and stock owners

Novavax executives and other stock owners filed with the SEC include:

• Stanley Erck,
  President, Chief Executive Officer, Director
• Gregory Glenn,
  President, Research and Development
• John Trizzino,
  Executive Vice President, Chief Commercial Officer, Chief Business Officer
• John Herrmann,
  Executive Vice President, Chief Legal Officer
• Stanley Charles Erck,
  Pres, CEO & Director
• Dr. Gregory M. Glenn,
  Pres of R&D
• John Joseph Trizzino B.S., M.B.A.,
  Exec. VP and Chief Bus. & Commercial Officer
• John A. Herrmann III,
  Exec. VP, Chief Legal Officer & Corp. Sec.
• James Young,
  Independent Chairman of the Board
• Michael McManus,
  Independent Director
• Gary Evans,
  Independent Director
• Richard Douglas,
  Independent Director
• Rachel King,
  Independent Director
• Gregory Covino,
  Chief Financial Officer, Executive Vice President
• David Mott,
  Independent Director
• Rajiv Modi,
  Director
• Gregg Alton,
  Director
• Brian Webb,
  Senior Vice President - Manufacturing
• Brian Rosen,
  Senior Vice President - Commercial Strategy
• Jody Lichaa,
  Senior Vice President - Quality Assurance
• Filip Dubovsky,
  Senior Vice President, Chief Medical Officer
• Silvia Taylor,
  Senior Vice President of Investor Relations and Corporate Affairs
• Frank Czworka,
  Senior Vice President - Global Sales
• Ben Machielse,
  Executive Vice President - CMC
• Jill Hoyt,
  Chief Human Resource Officer, Executive Vice President
• Troy Morgan Esq., J.D.,
  Sr. VP & Chief Compliance Officer
• Troy Morgan Esq.,
  Sr. VP & Chief Compliance Officer
• Silvia Taylor M.B.A., MBA,
  Sr. VP of Global Corp. Affairs & Investor Relations
• Biegie Lee,
  Sr. VP & Chief Information Officer
• Dr. Gale E. Smith,
  Sr. VP of Discovery & Pre-Clinical Research and Chief Scientist
• Richard P. Crowley,
  Exec. VP & COO
• James Patrick Kelly C.F.A.,
  Exec. VP, CFO & Treasurer
• Richard J Rodgers,
  
• Margaret G Mcglynn,
  
• Gail Boudreaux,
  Director
• Barclay A Phillips,
  SVP, Chief Financial Officer
• Mark J Casey,
  EVP, CLO & Corporate Secretary
• Mitchell J Kelly,
  Director
• Susan B Bayh,
  Director
• Ford R Lynch,
  Sr. VP Marketing and Sales
• John A Lambert,
  Director
• Thomas Scott Johnston,
  Vice President, Strategy
• Pharmaceuticals Inc King,
  10% owner
• John O Jr Marsh,
  Director
• Strategic Investments Llcgr...,
  
• Denis M Odonnell,
  Director
• Ronlad H Walker,
  Director
• Frederick W Driscoll,
  VP, CFO & Treasurer
• James B Tananbaum,
  Director
• Evdoxia E Kopsidas,
  Dir.Fin.,Int.Princ.Acctg.Off.
• Jim Robinson,
  VP,Technical & Qual. Operation
• D Craig Wright,
  Chief Scientific Officer
• Patricia Hall,
  Chief Accounting Officer
• Nelson M Sims,
  President/CEO
• Raymond Joseph Hage,
  VP - Business Development
• Russell P Wilson,
  SVP, Business Development
• Len F Stigliano,
  VP, CFO and Treasurer
• Ann P Mcgeehan,
  General Counsel/Secr
• Timothy Jon Hahn,
  SVP, Manufacturing & PD
• Pharmaceuticals Ltd Satelli...,
  
• Dennis W Genge,
  VP, Treasurer,CFO
• J Michael Md Lazarus,
  Director
• Penny Heaton,
  Chief Medical Officer
• Jeffrey Wayne Church,
  VP, CFO, Treasurer & Corp. Sec
• Rahul Singhvi,
  Sr VP, COO
• Thomas P Monath,
  Director
• Elaine O'hara,
  EVP, Chief Strategy Officer
• John C Jacobs,
  President and CEO
• James Patrick Kelly,
  EVP, CFO and Treasurer